Abstract
The antiquated legal standard that natural laws and products are not eligible for patent protection is ill-suited for gene and diagnostics patents. Here, I propose a new, technology-agnostic framework for determining patent eligibility that is tailored to the meet the US Constitutional objective of promoting innovation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have